China, Sept. 1 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-arm, Phase II clinical study of camrelizumab combined with anlotinib as second-line treatment for thymic carcinoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600131276
Registration Time: 2026/08/31
Type: Interventional study
Primary Sponsor: Zhejiang Cancer Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340836
Published by HT Digital Content Services with permission from Health Daily Digest....